Bezlotoxumab denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab as Not FDA-Approved

A not-FDA-approved denial almost always reflects either an administrative coding error — the drug or indication was coded in a way that did not match the FDA-approved labeling — or Aetna's reviewer applied the denial code in error. Bezlotoxumab (brand name Zinplava) received FDA approval and has a current prescribing label. If the drug was prescribed for its FDA-approved indication, this denial is almost certainly the result of a paperwork or coding issue rather than a substantive coverage dispute.

## Why This Denial Is Appealable

Because the denial rests on a factual premise — that the drug lacks FDA approval — that is demonstrably incorrect for the approved indication, this is one of the most straightforward denial types to overturn. The appeal primarily requires presenting the FDA approval documentation and confirming that the prescription and billing matched the approved indication.

## Federal Appeal Framework

• Pre-appeal inquiry: Before filing a formal appeal, call Aetna's member services and ask the reviewer to confirm whether the denial was a coding error. Sometimes this resolves the issue without a formal appeal.
• Internal appeal (ERISA §503 / ACA): If a quick correction is not possible, file a formal internal appeal within the deadline on your denial notice.
• External review (ACA §2719): If the internal appeal is upheld, request IRO review. The window is approximately four months from the final internal denial.
• Expedited track: Available with prescriber certification of urgent medical need.

## Concrete Appeal Steps

1. Download the current FDA prescribing label for bezlotoxumab (Zinplava) from the FDA website or DailyMed — this is your primary exhibit. 2. Confirm that the NDC code, diagnosis code (ICD-10), and procedure or drug code submitted on the claim match the FDA-approved indication. 3. Ask your prescriber or pharmacist to verify the submission codes. 4. Request the specific basis for the not-approved determination from Aetna in writing. 5. Submit the corrected claim or formal appeal with the FDA label and a prescriber attestation that the use is within the approved indication.

## Documentation to Gather

• FDA prescribing label (Zinplava): Current version downloaded from FDA.gov or DailyMed, with the approved indication section highlighted.
• Claim coding review: Confirmation from the prescriber or pharmacy that the NDC, ICD-10 diagnosis code, and drug administration code on the claim are correct.
• Prescriber attestation letter: Brief statement confirming the drug was used within its FDA-approved indication.
• Diagnosis documentation: Laboratory confirmation of C. difficile infection to establish that the clinical context matches the approved indication.

## Criteria-Mapping Structure

This appeal is primarily a factual correction rather than a clinical argument. Present: (1) the FDA approval date and approved indication from the label; (2) the indication under which the drug was prescribed, as stated by the prescriber; (3) the claim codes and confirmation that they match the approved indication. If Aetna's policy attaches any additional conditions to coverage of FDA-approved drugs, identify each condition and provide the corresponding chart evidence. Keep the submission concise and evidence-anchored.